Summary
Anticonvulsant drug-induced disorders in mineral and bone metabolism are apparently quite common. Current evidence indicates that these drugs derange bone metabolism, both through induction of increased hepatic catabolism of vitamin D and its biologically active products, as well as by direct effects on membrane cation transport systems.
The significant clinical manifestations of the disorder include rickets with defective bone development, decreased bone mass with increased risk of pathological fracture and reductions in serum calcium levels which may predispose to increased seizure frequency. There is a broad range of clinical presentation with a number of factors — drug dose, duration of therapy, vitamin D intake, amount of sunlight exposure, degree of physical activity and presence of other concurrent diseases — which appear to determine the severity of the clinical manifestations. Current evidence indicates that appropriate vitamin D and calcium supplementation can significantly reduce the clinical manifestations of this disorder.
All patients receiving chronic anticonvulsant drug therapy should be carefully evaluated for the presence of drug-induced osteomalacia and treated appropriately with vitamin D. This is especially important in those patients in whom the presence of multiple risk factors indicates an increased likelihood of deranged mineral metabolism.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Birge, S.J. and Haddad, J.G.: 25-hydroxycholecalciferol stimulation of muscle metabolism. The Journal, of Clinical Investigation 56: 1100–1107 (1975).
Christiansen, C; Rodbro, P. and Lund, P.: Incidence of anticonvulsant osteomalacia and effect of vitamin D: controlled therapeutic trial. British Medical Journal 4: 695–701 (1973).
Christiansen, C; Rodbro, P. and Nielsen, CT.: Iatrogenic osteomalacia in epileptic children. A controlled therapeutic trial. Acta Paediatric Scandinavica 64: 219–224 (1975).
Christiansen, C; Rodbro, P. and Ole, S.: Anticonvulsant action of vitamin D in epileptic patients? A controlled pilot study. British Medical Journal 2: 258–259 (1974).
Conney, A.H.: Pharmacologic implications of microsomal enzyme induction. Pharmacology Reviews 19: 317–366 (1967).
Dent, CE.; Richens, A.; Rowe, D.J.F. and Stamp, T.C.B.: Osteomalacia with long-term anticonvulsant therapy in epilepsy. British Medical Journal 4: 69–72 (1970).
Glynne, A.; Hunter, I.P. and Thomson, J.A.: Pseudo-hypoparathyroidism with paradoxical increase in hypocalcemic seizures due to long-term anticonvulsant therapy. Postgraduate Medical Journal 48: 632–636 (1972)
Haddad, J.G.; Jr. and Hahn, T.J.: Natural and synthetic sources of circulating 25-hydroxyvitamin D in man. Nature (Lond.) 244: 515–518 (1973).
Hahn, T.J.; Birge, S.J.; Scharp, C.R. and Avioli, L.V.: Phenobarbital-induced alterations in vitamin D metabolism. The Journal of Clinical Investigation 51: 741–748 (1972a).
Hahn, T.J.; Boisseau, V.C and Avioli, L.V.: Effect of chronic corticosteroid administration on diaphyseal and metaphyseal bone mass. The Journal of Clinical Endocrinology and Metabolism 39: 274–282 (1974a).
Hahn, T.J.; Halstead, L.R.; Scharp, CR. and Haddad, J.G.: Enhanced biotransformation and biologic efficacy of vitamin D following phenobarbital administration in the rat. Clinical Research 23: 111 A, (1975a).
Hahn, T.J.; Hendin, B.A.; Scharp, C.R.; Boisseau, V.C and Haddad, J.G., Jr.: Serum 25-hydroxycalciferol levels and bone mass in children on chronic anticonvulsant therapy. New England Journal of Medicine 292: 550–554, (1975b).
Hahn, T.J.; Hendin, B.A.; Scharp, CR. and Haddad, J.G., Jr.: Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults. New England Journal of Medicine 287: 900–904 (1972b).
Hahn, T.J.; Scharp, CR. and Avioli, L.V.: Effect of phenobarbital administration on the subcellular distribution of vitamin D3−3 H in rat liver. Endocrinology 94: 1489 (1974b).
Holick, M.F. and DeLuca, H.F.: Vitamin D metabolism. Annual Review of Medicine 25: 349–367 (1974).
Hunter, J.; Maxwell, J.D.; Stewart, D.A.; Parsons, V. and Williams, R.: Altered calcium metabolism in epileptic children on anticonvulsants. British Medical Journal 2: 202–204(1971).
Jenkins, M.V.; Harris, M. and Wills, M.R.: The effect of phenytoin on parathyroid extract and 25-hydroxy-cholecalciferol-induced bone resorption: adenosine 3′5′ cyclic monophosphate production. Calcified Tissue Research 16: 163–167 (1974).
Jubiz, W.; Meikle, A.W.; Levinson, R.A.: Effect of diphenylhydantoin on the metabolism of dexamethasone: mechanism of the abnormal dexamethasone suppression in humans. New England Journal of Medicine 283: 11–14 (1970).
Koch, H V.; Kraft, D.; von Heuath, D. et al.: Influence of diphenylhydantoin and phenobarbital on intestinal calcium transport in the rat. Epilepsia 13: 829–841 (1972).
Kruse, R.: Osteopathien bei antiepileptischer langzeit-therapie (vorlaufige mitteilung) Mschr. Kinderheilk. 116: 378–380 (1968).
Linde, J.; Molholm-Hansen, J.; Siersbaek-Nielsen, K. and Fuglang-Fredriksen, V.: Bone density in patients receiving long-term anticonvulsant therapy. Acta Neurologica Scandinavica 47: 650–651 (1971).
Levin, W.; Welch, R.M. and Conney, A.H.: Effect of chronic pheonbarbital treatment on the liver microsomal metabolism and uterotrophic action of 17β-estradiol. Endocrinology 80: 135–140 (1967).
Liakakos, D.; Papadopoulos, Z.; Vlachos, P.; Boviatsi, E. and Varonos, D.D.: Serum alkaline phosphatase and urinary hydroxyproline values in children receiving phenobarbital with and without vitamin D. Journal of Pediatrics 87: 291–296 (1975).
Lifshitz, F. and Maclaren, N.K.: Vitamin D-dependent rickets in institutionalised mentally retarded children receiving long-term anticonvulsant therapy: I. A survey of 288 patients. Journal of Pediatrics 83: 612–620 (1973).
Maclaren, N.K. and Lifshitz, F.: Vitamin D dependency rickets in institutionalised, mentally retarded children on long-term anticonvulsant therapy: II. The response to 25-hydroxycholecalciferol and vitamin D. Pediatric Research 7: 914–923 (1973).
Linde, J.; Molholm-Hansen, J.; Siersbaek-Nielsen, K. and Fuglang-Fredriksen, V.: Bone density in patients receiving long-term anticonvulsant therapy. Acta Neurologica Scandinavica 47: 650–651 (1971).
Marsden, CD.; Reynolds, E.H.; Parsons, V.; Harris, R. and Duchan, L.: Myopathy associated with anticonvulsant osteomalacia. British Medical Journal 4: 526–527 (1973).
Richens, A. and Rowe, D.J.F.: Disturbance of calcium metabolism by anticonvulsant drugs. British Medical Journal 3: 73–76 (1970).
Rodbro, P.; Christiansen, C. and Lund, M.: Development of anticonvulsant osteomalacia in epileptic patients on phenytoin treatment. Acta Neurologica Scandinavica 50: 527–532 (1974).
Schaefer, K.; Kraft, D. and Von Herrath, D.: Intestinal absorption of vitamin D3 in epileptic patients and phenobarbital-treated rats. Epilepsia 13: 509–519 (1972).
Silver, J.; Neale, G. and Thompson, G.R.: Effect of phenobarbitone treatment on vitamin D metabolism in mammals. Clinical Science and Molecular Medicine 46: 433–448 (1974).
Stamp, T.C.B.; Round, J.M.; Rowe, D.J.F. and Haddad, J.G.: Plasma levels and therapeutic effect of 25-hydroxycholecalciferol in epileptic patients taking anticonvulsant drugs. British Medical Journal 4: 9–12 (1972).
Tolman, K.G.; Jubiz, W.; Sannella, J.J.; Madsen, J.A. et al.: Osteomalacia associated with anticonvulsant drug therapy in mentally retarded children. Pediatrics 56: 45–51 (1975).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hahn, T.J. Bone Complications of Anticonvulsants. Drugs 12, 201–211 (1976). https://doi.org/10.2165/00003495-197612030-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-197612030-00003